Prof. Dr. Levent Kabasakal

PUBLICATIONS

Published Articles

  1. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer?Demirci E, Kabasakal L, Şahin OE, Akgün E, Gültekin MH, Doğanca T, Tuna MB, Öbek C, Kiliç M, Esen T, Kural AR.Nucl Med Commun. 2019 Jan;40(1):86-91. doi: 10.1097/MNM.0000000000000942. 
  2. Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.Abuqbeitah M, Demir M, Çavdar İ, Tanyildizi H, Yeyin N, Uslu-Beşli L, Kabasakal L, Işıkcı Nİ, Sönmezoğlu K.Radiat Environ Biophys. 2018 Nov;57(4):395-404. doi: 10.1007/s00411-018-0757-2. Epub 2018 Oct 8. 
  3. Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer. Abuqbeitah M, Demir M, Kabasakal L, Çavdar İ, Uslu-Beşli L, Yeyin N, Razavikhosroshahi S, Sönmezoğlu K. Nucl Med Commun. 2018 Nov;39(11):969-975. doi: 10.1097/MNM.0000000000000900. 
  4. ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM 68Ga-PSMA-11 PET SCAN. Demirci E, Toklu T, Yeyin N, Ocak M, Alan-Selcuk N, Araman A, Kabasakal L.Radiat Prot Dosimetry. 2018 Dec 1;182(4):518-524. doi: 10.1093/rpd/ncy111. 
  5. Demirci E., Kabasakal L., Toklu T., Ocak M., Alan-Selcuk N., Sahin O.E., Araman A. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours (NETs) including high-grade (WHO G3) NETs: Response to treatment and long-term survival update” submitted to Nucl Med Commun in December 2017 
  6. Demirci E, Has Simsek D, Kabasakal L, Mülazimoğlu M. Abdominal Splenosis Mimicking Peritoneal Metastasis in Prostate-Specific Membrane Antigen PET/CT, Confirmed With Selective Spleen SPECT/CT. Clin Nucl Med. 2017 Dec;42(12):e504-e505. doi: 10.1097/RLU.0000000000001878. 
  7. Uslu-Beşli L, Kabasakal L, Sağer S, Cicik E, Asa S, Sönmezoğlu K. Orbital flourine-18-fluorodeoxyglucose positron emission tomography in patients with Graves' disease for evaluation of active inflammation. Nucl Med Commun. 2017 Nov;38(11):964-970. doi: 10.1097/MNM.0000000000000737. 
  8. Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, Yücetaş U, Demirdağ Ç, Erdoğan SM, Kabasakal L; Members of Urooncology Association, Turkey. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1806-1812.  doi: 10.1007/s00259-017-3752-y.  
  9. Kabasakal L., Toklu T., Yeyin N., Demirci E., AbuQbeita M., Ocak M., Aygün A., Karayel E., Pehlivanoğlu H., Selçuk N. 177Lu-PSMA-617 prostate specific membrane antigen (PSMA) inhibitor therapy in patients with castration resistant prostate cancer: Stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017 Jun 1;26(2):62-68. doi: 10.4274/mirt.08760. 
  10. Kabasakal L., Demirci E., Nematyazar J., Akyel R., Razavi B., Ocak M., Aygun A., Obek C., Kural AR. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nucl Med Commun. 2017 Feb;38(2):149-155.  
  11. Caglar E, Doğusoy G, Kabasakal L, Dobrucali A. Long-Term Palliative Effect of Stenting in Gastric Outlet Obstruction Due to Transarterial Chemoembolization with Yttrium-90 in a Patient with Metastatic Neuroendocrine Tumor. Clin Endosc. 2016 Sep;49(5):479-482. 
  12. Demir M, Abuqbeitah M, Uslu-Beşli L, Yıldırım Ö, Yeyin N, Çavdar İ, Vatankulu B, Gündüz H, Kabasakal L. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot. 2016 Jun;36(2):269-78. doi: 10.1088/0952-4746/36/2/269. 
  13. Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L.  Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.  Nucl Med Commun. 2016 Nov;37(11):1169-79. doi: 10.1097/MNM.0000000000000566. 
  14. Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1976-83. doi: 10.1007/s00259-015-3125-3. 
  15. Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015 Jun;36(6):582-7. doi: 10.1097/MNM.0000000000000290. 
  16. Kabasakal L., Demirci E. “PSMA PET/CT Imaging and Therapy”.  Journal of Imaging and Interventional Radiology.2015.1 (2):16 pg 1-4 
  17. Bas A, Samanci C, Gulsen F, Cantasdemir M, Kabasakal L, Kantarci F, Numan F. Evaluation of Liver Stiffness After Radioembolization by Real-Time ShearWave™ Elastography: Preliminary Study. Cardiovasc Intervent Radiol. 2014 Nov 21. 
  18. Demirci E., Ocak M., Kabasakal L., Decristoforo C., Talat Z., Halaç M., Kanmaz B. 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1461-2 
  19. Aksoy SY, Asa S, Ozhan M, Ocak M, Sager MS, Erkan ME, Halac M, Kabasakal L, Sönmezoglu K, Kanmaz B. FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection.  Eur J Nucl Med Mol Imaging. 2014 Mar; 41(3): 556-64. 
  20. Deveci EK,  Ocak M,  Bozkurt MF,  Türker S.,  Kabasakal L., Uğur O. The Diagnostic Efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with 111In-Pentetrotide in the Detection of Neuroendocrine Tumours. Mol Imaging Radionucl Ther. 2013 Dec;22(3):76-84 
  21. Sager S., Kabasakal L., Ocak M., Maecke H., Uslu L., Halac M., Asa S., Sager G., Onsel C., Kanmaz B., Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images. Nucl Med Commun. 2013 Dec;34(12):1190-5. 
  22. Asa S, Yılmaz S, Kaya R, Sağer S, Halac M, Kabasakal L. Imaging of multiple brown tumors both in FDG (18F) and 68Ga DOTA-TATE PET/CT studies. Rev Esp Med Nucl Imagen Mol. 2013 Nov-Dec;32(6):404-5 
  23. Ocak M., Demirci E., Kabasakal L., Aygun A., Tatar OR., Araman A., Kanmaz B.Evaluation and Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013 Nov;34(11):1084-9. 
  24. Demirci E., Ocak M., Kabasakal L., Araman A., Ozsoy Y., Kanmaz B. Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT imaging in the same patient group with Neuroendocrine Tumors. Nucl Med Commun. 2013 Aug;34(8):727-32. 
  25. Kabasakal L., Ocak M. Gastroenteropankreatik Tümörlerde Peptid Reseptör Radyonüklit Tedavi ve Y-90 Mikroküre Tedavisi. Turkiye Klinikleri J Med Oncol-Special Topics 2013;6(2):38-45 
  26. Hatipoglu E, Kepicoglu H, Rusen E, Kabasakal L, Gundogdu S, Kadioglu P. Von Hippel Lindau disease with metastatic pancreatic neuroendocrine tumor causing ectopic Cushing's syndrome. Neuro Endocrinol Lett. 2013;34(1):9-13. 
  27. Sager S, Kabasakal L, Halac M, Maecke H, Uslu L, Önsel Ç, Kanmaz B. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers. Clin Nucl Med. 2013 May;38(5):321-5. 
  28. Yılmaz S., Ocak M., Asa S., Gulsen F., Halac M., Kabasakal L. Appearance of intracranial meningioma in FDG and (68)Ga-DOTATATE PET/CT. Rev Esp Med Nucl Imagen Mol. 2013 Jan;32(1):60-1 
  29. Yılmaz S., Ocak M., Asa S., Aliyev A., Ozhan M., Halac M., Sager S., Kabasakal L., Sonmezoglu K. The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions. Eur J Nucl Med Mol Imaging. 2012 Oct;39(10):1660-1 
  30. Kabasakal L., Demirci E., Ocak M., Decristoforo C., Araman A., Ozsoy Y., Ulsu I., Kanmaz B. Comparison of (68)Ga-DOTATATE and (68)Ga-DOTA-NOC PET/CT imaging in the same patient group with neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2012, Aug;39(8):127-7. 
  31. Aliyev A., Kabasakal L., Ocak M., Hacıyev Y., Ozhan M., Vural Ö., Ozturk Ö., Demirkaya A.,  Uslu İ. Intraoperative localization of recurrent medullary carcinoma of the thyriod using 99mTc-HYNIC-TATE and a surgical gamma probe. Clin Nucl Med . 2011;36 (9):831-3. 
  32. Ocak M., Helbok A., von Guggenberg E., Ozsoy Y., Kabasakal L., Kremser L., Decristoforo C. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative. Nucl Med Biol. 2011; 38(2): 171-9. 
  33. Selcuk NA, Onsel C, Ozturk S, Gurmen T, Gulbaran M, Sager S, Kabasakal L, Sayman HB, Uslu I. Intravascular radiation therapy with a Re-188 liquid-filled balloon in patients with in-stent restenosis. Nucl Med Commun. 2010 Aug;31(8):746-52 
  34. Aliyev A, Kabasakal L, Simsek O, Paksoy M, Halac M, Uslu I. Ectopic parathyroid adenoma localized with MIBI scintigraphy and excised with guide of macroaggregated human serum albumin injection. Clin Nucl Med. 2010 Mar;35(3):151-3. 
  35. Sager S, Halac M, Selcuk N, Dogan I, Kabasakal L, Onsel C, Uslu I. Temporal relationship between gastroesophageal reflux and rate of gastric emptying in children. Nucl Med Commun. 2010 Dec;31(12):1059-62. 
  36. Kanmaz B, Sayman HB, Alan N, Devranoglu G, Nisli S, Sonmezoglu K, Kabasakal L, Halac M, Onsel C, Uslu I. The value of different washout parameters in the evaluation of renal transplants by technetium-99m-ethylene- l-l-dicysteine. Hell J Nucl Med. 2010 May-Aug;13(2):127-31. 
  37. Ekici H, Sontas BH, Toydemir TS, Senmevsim O, Kabasakal L, Imre Y. The effect of prepubertal ovariohysterectomy on spine 1 mineral density and mineral content in puppies: A preliminary study.Res Vet Sci. 2007 Feb;82(1):105-109. 
  38. Balcı, TA, Kabasakal L. Is I-131 scanning proper for the follow-up management of the patients with malignant struma ovarii without performing the thyroidectomy?. Gyneacol Oncol, 2005 
  39. Ahmed ASM, Demir M, Kabasakal L, Uslu İ. A dynamic phantom for nuclear medicine studies. Med Phys 2005;32:530-538  
  40. Massardo T, Alonso O, Llamas-Ollier A, Kabasakal L, Ravishankar U, Morales R, Delgado L, Padhy AK. Planar Tc99m--sestamibi scintimammography should be considered cautiously in the axillary evaluation of breast cancer protocols: results of an international multicenter trial. BMC Nucl Med. 2005 Jul 27;5:4.  
  41. Ekici H, Sontas BH, Toydemir TS, Senmevsim O, Kabasakal L, Imre Y.Effect of prepubertal ovariohysterectomy on bone mineral density and bone mineral content in puppies. Acta Vet Hung. 2005;53(4):469-78. 
  42. Kabasakal L,Selçuk NA, Shaffipour H, Ozmen O, Onsel Ç, Uslu İ Treatment of iodine negative thyroglobulin positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. Eur J Nucl Med Mol Imaging. 2004. 
  43. Kabasakal L. Treatment of iodine negative thyroglobuline positive thyroid cancer patients: Do we miss the target when we shot in the dark? Nucl Med Commun; 2003:  
  44. Fettich J, Colarinha P, Fischer S, Frokier J, Gordon I, Hahn K, Kabasakal L, Mann M, Mitjavila M, Olivier P, Piepsz A, Porn U, Sixt R, Van Velzen J. Guidelines for direct radionuclide cystography in children, Eur J Nucl Med Mol Imaging, 2003;30:  
  45. Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F, Gordon I, Hahn K, Kabasakal L, Mann M, Mitjavila M, Piepsz A, Porn U, Sixt R, Van Velzen J. Guidelines for radioiodinated MIBG scintigraphy in children, Eur J Nucl Med Mol Imaging, 2003;30:  
  46. Kabasakal L, Turkmen C, Özmen Ö, Alan N, Onsel Ç, Uslu I. Is furosemide administration effective in improving the accuracy of determination of differential renal function by means of technetium-99m DMSA in patients with hydronephrosis? Eur J Nucl Med Mol Imaging. 2002;29: 1433-1437.  
  47. Demir M, Konukoğlu D, Kabasakal L, Yelke HK, Ergen K, Ahmed S. The effect of exposure of Co-60 on the oxidant/antioxidant status among radiation victims. J Env Rad, 2003; 64:19-25. ( 9 puan) 
  48. Massordo T, Alonso O, Kabasakal L, Llamas-Olier A, Shankar UR, Zhu H, Delgado L, Gonzales P, Mut F, Padhy AK. Diagnostic value of Tc-99m methylene diphosphonate and Tc-99m pentavalent DMSA compared with Tc-99m sestamibi for palpable breast lesions. J Nucl Med, 2002;43:882-888.  
  49. Alonso O, Massardo T, Delgado LB, Horwvath J, Kabasakal L, Llamas OA, Maunda KK, Padhy AK, Shankar UR. Is (99m)Tc-sestamibi scintimammography complementary to conventional mammography for detecting breast cancer in patients with palpable masses? J Nucl Med. 2001 Nov;42(11):1614-21.  
  50. Gordon I, Colarinha P, Fettich J, Ficher S, Frokier J, Hahn K, Kabasakal L, Mitjavilla M, Olivier P, Piepsz A, Porn U, Sixt R, Velzen J. Guidelines for indirect radionuclide cystography. Eur J Nucl Med;28: BP16-20.  
  51. Gordon I, Colarinha P, Fettich J, Ficher S, Frokier J, Hahn K, Kabasakal L, Mitjavilla M, Olivier P, Piepsz A, Porn U, Sixt R, Velzen J. Guidelines for standard and diuretic renogram in children. Eur J Nucl Med;28: BP21-30.  
  52. Doğruca Z, Kabasakal L, Yapar F, Nişli C, Vural AV, Onsel Ç. A comparison of Tl-201 stress-reinjection-prone SPECT and Tc-99m-sestamibi gated SPECT in the differentiation of inferior wall defects from artifacts. Nucl Med Commun. 2000 Aug;21(8):719-27  
  53. Erdil TY, Onsel Ç, Kanmaz B, Caner B, Sonmezoglu K, Ciftci I, Turoğlu T, Kabasakal L, Sayman HB, Uslu I. Comparison of 99m Tc-methoxyisobutyl isonitrile and Tl-201 scintigraphy in visualization of suppressed thyroid tissue. Journal of Nuclear Medicine, 2000;41: 1163-1167. (3 puan) 
  54. Erdil TY, Ozker K, Kabasakal L, Kanmaz B, Sonmezoğlu K, Atasoy KC, Turoğlu HT, Uslu I, Isitman AT, Onsel Ç. Correlation of Tc-99m MIBI and Tl-201 retention in solitary cold thyrois nodules with postoperative histopathology. European Journal of Nuclear Medicine. 2000; 27: 713-720.  
  55. Yeni SN, Kabasakal L, Yalçınkaya C, Nişli C, Dervent A. Ictal and interictal SPECT findings in childhood absence epilepsy. Seizure. 2000;9: 265-269.) 
  56. Kanmaz B, Erdil TY, Yardi OF, Sayman HB, Kabasakal L, Sonmezoglu K, Onsel Ç. Duren M, Nişli C, Ozcan K, Uslu İ. The role of Tc-99m tetrofosmin in the evaluation of thyroid nodules. Nuclear Medicine Communications. 2000; 21: 333-339.  
  57. L. Kabasakal. Technetium-99m ethylene dicysteine: a new renal tubular function agent. European Journal of Nuclear Medicine, 2000;27:351-357.  
  58. Kabasakal L, M. Kalaç, C. Nişli, O. Oğuz, Ç. Önsel, G. Çivi, İ. Uslu. The effect of P-glycoprotein function inhibition with cyclosporin-A on biodistribution of Technetium-99m sestamibi. Clinical Nuclear Medicine, 2000;25:20-23.  
  59. K. Özker, B.D. Collier, D.J. Lindner, L. Kabasakal, Y. Liu, A.Z. Krasnow, R.S. Hellman, S.D. Edwards, C.R. Bourque, P.D. Crane. Biodistribution of Tc-99m labelled 5-thio-d-glucose. Nuclear Medicine Communications, 1999;20: 1055-1058.  
  60. L. Kabasakal, M. Halaç, E. Alkan, N. Özçelik, Ç. Önsel, İ. Uslu. Reproducibility of Tc-99m EC Clearance. European Journal of Nuclear Medicine 1999;26:900-902.  
  61. L. Kabasakal, M. Halaç, A.F. Yapar, E. Alkan, B. Kanmaz, Ç: Önsel, K. Sönmezoğlu, M. Ayaz, B. Kalender, H.B. Sayman, İ. Uslu. Prospective validation of single plasma sample Tc-99m EC clearance in adults. Journal of Nuclear Medicine 1999;40:429-431. 
  62. K. Sönmezoğlu, T.Y. Erdil, M. Demir, H.B. Sayman, L. Kabasakal, ÖF. Yardı, H. Özkara, M.C. Mat, K. Solanki, K.E. Britton. Evaluation of renal function in low-dose cyclosporine-treated patients using Tc-99 m diaminocyclohexane: a cationic tubular excretion agent. European Journal of Nuclear Medicine;1998:25: 1630-1636.  
  63. L. Kabasakal, T.Y. Erdil, M. Ayaz, S. Atay, K. Sönmezoğlu, B. Kanmaz, U. Ülkü, İ. Uslu, H.B. Sayman, Ç. Önsel. Evaluation of Tc-99m-EC in anuric hemodialysis patients. Indian Journal of Nuclear Medicine 1998;13: 42-44.  
  64. L. Kabasakal, A.F. Yapar, K. Özker, E. Alkan, S. Atay, N. Özçelik, Ç. Önsel. Simplified Technetium-99m-EC clearance in adults from a single plasma sample. Journal of Nuclear Medicine 1997;38:1784-1786.  
  65. K. Özker, L. Kabasakal, Y. Liu, R.S. Hellman, A. Işıtman, A.Z. Krasnow, B.D. Collier. Evaluation of Tc-99m-bicisate as a renal imaging. Nuclear Medicine Communucations 1997;18:771-775.  
  66. L. Kabasakal, Ç. Önsel. Simplified determination of technetium-99m ethylenedicysteine clearance from a single plasma sample: what is the upper normal range? European Journal of Nuclear Medicine 1996;23:1556-1557.  
  67. L. Kabasakal, B.D. Collier, R. Shaker, R.S. Hellman, S. Smart, K. Özker, A.Z. Krasnow, A.T. Işıtman. Enterogastric bile reflux during technetium-99m-sestamibi cardiac imaging. Journal of Nuclear Medicine 1996;37:1285-1288.  
  68.  M. Demir, L. Kabasakal, Ç. Önsel. Evaluation of radiation exposition rate from radioiodine treated hyperthyroid patients and radiation safety considerations. Nuclear Medicine Communications 1996;17:692-695  
  69. L. Kabasakal, K. Özker, M. Hayward, G. Akansel, O. Griffith, A.T. Işıtman, R. Hellman, D. Collier. Tc-99m-setamibi uptake in human breast carcinoma cell lines displaying glutathione associated drug resistance.European Journal of Nuclear Medicine 1996;23:568-570. 
  70. L. Kabasakal, S. Atay, V.A. Vural, K. Özker, K. Sönmezoğlu, İ. Uslu, A.T. Işıtman, Ç. Önsel. Evaluation of technetium-99m-ethylenedicysteine in renal disorders and determination of extraction ratio. Journal of Nuclear Medicine 1995;36:1398-1402. 
  71. L. Kabasakal, K. Devranoğlu, O. Arslan, T.Y. Erdil, K. Sönmezoğlu, İ. Uslu, H. Tolun, A.T. Işıtman, K. Özker, Ç. Önsel. Brain SPECT evaluation of the visual cortex in amblyopia. Journal of Nuclear Medicine 1995;36:1170-1174.  
  72. L. Kabasakal, H.T. Turoğlu, Ç. Önsel, K. Özker, İ. Uslu, S. Atay, T. Cansız, K. Sönmezoğlu, E. Altıok, A.T. Işıtman, T. Kapıcıoğlu, İ. Urgancıoğlu. Clinical comparison of technetium-99m-EC, technetium-99m-MAG3 and iodine-131-OIH in renal disorders. Journal of Nuclear Medicine 1995;36:224-228.  
  73. L. Kabasakal, K. Özker, A.T. Işıtman, Ç. Önsel. Relationship between the OIH and Tc-99m-EC clearances. Nuclear Medicine Communications 1994;15:1006-1007. 
  74.  K. Özker, Ç. Önsel, L. Kabasakal, H.B. Sayman, İ. Uslu, Ş. Bozluolcay, T. Cansız, T. Kapıcıoğlu, İ. Urgancıoğlu. Technetium-99m-N,N-ethylenedicysteine-A comparative study of renal scintigraphy with Tc-99m-MAG3 and iodine-131-OIH in patients with obstructive renal disease. Journal of Nuclear Medicine 1994;35:840-845.  

CONTACT - APPOINTMENT

               
0 (212) 296 88 84
0 (532) 366 79 08
lkabasakal@tsnm.org
prof.dr@leventkabasakal.com
Halaskargazi Caddesi Günaydın Apt. 12/6
Harbiye, Sisli İstanbul

Just fill in the form to schedule an appointment or ask questions. We will contact you as soon as possible.